tadalafil has been researched along with Prostatism in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 18 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y; Fukushi, T; Kaiho, Y; Kawasaki, Y; Koyama, J; Kyan, A; Sato, T | 1 |
| Anjiki, H; Hagiwara, K; Hayashida, M; Kurosawa, K; Nagamoto, S; Ogawa, K; Oka, S; Okaneya, T; Sakaguchi, K; Urakami, S; Yano, A | 1 |
| Chapple, CR; Henneges, C; Ilo, D; McVary, K; Roehrborn, CG; Viktrup, L | 1 |
| De Nunzio, C; Tubaro, A | 1 |
| Morisaki, Y; Murakami, M; Nishizawa, O; Takeda, M; Viktrup, L; Yokoyama, O; Yoshida, M | 1 |
| Casabé, A; Glina, S; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L | 1 |
| Oh-Oka, H | 1 |
| Masumori, N | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Auerbach, SM; Elion-Mboussa, A; Kaminetsky, JC; Montelongo, RM; Roehrborn, CG; Viktrup, L | 1 |
| Dmochowski, R; Kaminetsky, J; Klise, S; Kraus, S; Roehrborn, C; Xu, L | 1 |
| Albo, ME; Dmochowski, R; Klise, SR; Kraus, SR; Roehrborn, CG; Xu, L | 1 |
| Brock, GB; Broderick, GA; Elion-Mboussa, A; Roehrborn, CG; Viktrup, L; Watts, SD | 1 |
| Dmochowski, RR; Gomelsky, A | 1 |
| de la Rosette, JJ | 1 |
| Kaplan, SA | 1 |
| Choi, SB; Jeon, JH; Kang, KK; Kim, SH; Lee, SW; Park, JK; Zhao, C | 1 |
| Brock, GB; Donatucci, CF; Elion-Mboussa, A; Goldfischer, ER; Kissel, JD; Pommerville, PJ; Viktrup, L | 1 |
| Cerqueira, JB; de Moraes, MO; Jamacaru, FV; Josino, IR; Nogueira, EA; Regadas, RP; Reges, R; Silva, LF; Sucupira, DG | 1 |
| Hütter, J; Sandner, P; Stelte-Ludwig, B; Tinel, H | 1 |
| Auerbach, SM; Denes, BS; Esler, A; Kaminetsky, JC; McVary, KT; Roehrborn, CG; Sides, GD; Wachs, B; Young, JM | 1 |
2 review(s) available for tadalafil and Prostatism
| Article | Year |
|---|---|
Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment.
Topics: Acetylcholine Release Inhibitors; Botulinum Toxins, Type A; Drug Combinations; Humans; Laser Therapy; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Solifenacin Succinate; Sulfonamides; Tadalafil; Tamsulosin; Transurethral Resection of Prostate; Urological Agents | 2015 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
11 trial(s) available for tadalafil and Prostatism
| Article | Year |
|---|---|
Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Pilot Projects; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Solifenacin Succinate; Tadalafil; Urological Agents | 2019 |
Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Asian People; Double-Blind Method; Humans; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Tadalafil; Taiwan; Urological Agents | 2015 |
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing f
Topics: 5-alpha Reductase Inhibitors; Aged; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatism; Severity of Illness Index; Tadalafil | 2015 |
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Epidemiologic Methods; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Treatment Outcome; Urination; Urodynamics | 2010 |
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Time Factors; Urodynamics | 2010 |
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction.
Topics: Carbolines; Drug Administration Schedule; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatism; Reference Standards; Tadalafil; Urinary Bladder Neck Obstruction; Urodynamics | 2010 |
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phosphodiesterase Inhibitors; Probability; Prostatic Hyperplasia; Prostatism; Quality of Life; Reference Values; Risk Assessment; Severity of Illness Index; Tadalafil; Treatment Outcome; Urination Disorders; Urodynamics | 2010 |
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Aged; Carbolines; Erectile Dysfunction; Feasibility Studies; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Pyrimidines; Sulfonamides; Tadalafil; Treatment Outcome | 2011 |
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
Topics: Aged; Aged, 80 and over; Carbolines; Drug Administration Schedule; Epidemiologic Methods; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Treatment Outcome | 2011 |
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Sulfonamides; Tadalafil; Tamsulosin; Urinary Bladder, Overactive; Urination; Urodynamics | 2013 |
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil | 2007 |
8 other study(ies) available for tadalafil and Prostatism
| Article | Year |
|---|---|
Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Blood Pressure; Cholinergic Antagonists; Humans; Male; Patient Selection; Penis; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Tadalafil | 2019 |
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
Topics: Carbolines; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic; Regression Analysis; Severity of Illness Index; Tadalafil; Urination | 2015 |
Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, random
Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil | 2015 |
Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, rand
Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil | 2015 |
Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.
Topics: Carbolines; Drug Administration Schedule; Humans; Male; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Urodynamics | 2010 |
Editorial comment.
Topics: Carbolines; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Quality of Life; Risk Assessment; Tadalafil; Treatment Outcome; Urination Disorders | 2010 |
Editorial comment.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Quality of Life; Tadalafil; Treatment Outcome; Urination Disorders | 2010 |
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |